GHK-Cu Tracker App
Dosen loggen, Hautfortschritt verfolgen und Haardichte überwachen
GHK-Cu ist ein natürlich vorkommender Kupfer-Komplex, der die Kollagensynthese und Geweberegeneration reguliert. Shotlee trackt jede Anwendung, jedes Hautfoto und jeden Labormarker in einer kostenlosen App.
Was ist GHK-Cu?
GHK-Cu (Glycyl-L-histidyl-L-lysin) ist ein Tripeptid, das natürlicherweise im menschlichen Plasma vorkommt. Die Konzentration sinkt mit dem Alter deutlich, was mit einer verringerten Regenerationsfähigkeit der Haut verbunden ist.
GHK-Cu hat ein duales Profil: Topische Formulierungen sind als kosmetische Inhaltsstoffe weit verbreitet, während injizierbares GHK-Cu in der Forschung für systemische regenerative Effekte untersucht wird. Shotlee hilft Ihnen, beide Anwendungsformen präzise zu dokumentieren.
Protokoll-Optionen
ATTAIN-1 (72 weeks)
Up to 27.3 lbs
Average weight reduction in adults without type 2 diabetes in the Phase 3 ATTAIN-1 obesity trial.
Phase 2 Weight Loss
~14.7%
Body weight reduction at 36 weeks in the Phase 2 obesity trial (Wharton et al., NEJM 2023).
Forschungshighlights
Activates GLP-1 receptors in the brain to reduce appetite and cravings
Slows gastric emptying to prolong feelings of fullness after meals
Enhances glucose-dependent insulin secretion for better blood sugar control
Small molecule structure survives stomach acid without special formulation
Absorbs effectively regardless of food intake — no fasting required
Maintains consistent blood levels with once-daily oral dosing
Was Sie in Shotlee tracken können
Week 1-2
3 mg daily
Starting dose
Week 3-4
6 mg daily
First escalation
Week 5-8
12-24 mg daily
Titration phase
Maintenance
36-45 mg daily
Target dose
Foundayo vs Injectable GLP-1s
Oral Convenience
Once-daily pill taken with or without food. No needles, no refrigeration, no injection site rotation. Ideal for needle-phobic patients.
Non-Peptide Structure
Unlike Rybelsus (oral semaglutide), Foundayo's small molecule design means no fasting requirement and better absorption flexibility.
Easier Manufacturing
Small molecules are cheaper and faster to produce than biologic peptides, potentially reducing drug shortages and lowering costs.
Global Access Potential
No cold chain storage required for pills. Easier worldwide distribution including developing markets where refrigeration is limited.
Who Is Foundayo Best For?
Ideal Candidates
Needle-phobic patients. Those who struggled with Rybelsus fasting restrictions. People with irregular schedules. Patients starting GLP-1 therapy for the first time. Those who prefer daily pills over weekly injections.
Consider Alternatives If
You need maximum weight loss (injectable tirzepatide may be stronger). You prefer weekly dosing over daily pills. You respond well to current injectable GLP-1s. You want dual GIP/GLP-1 agonist effects (tirzepatide).
Side Effects
Common (Similar to All GLP-1s)
Nausea (most common, especially during dose escalation). Vomiting. Diarrhea. Constipation. Decreased appetite. These typically improve over time and with slower dose titration.
Clinical Trial Observations
Side effect profile similar to injectable GLP-1s. GI effects typically mild to moderate in severity. Improved significantly with gradual dose escalation. No unexpected safety signals in Phase 3 data. Well-tolerated overall in ATTAIN and ACHIEVE trials.
Development Timeline
2023:
Phase 2 results published in NEJM showing ~14.7% weight loss at 36 weeks
2025:
Positive Phase 3 ATTAIN (obesity) and ACHIEVE (T2D) trial readouts reported
Late 2025:
Eli Lilly announces "Foundayo" as the brand name for orforglipron
2026:
Regulatory submissions to FDA for obesity and type 2 diabetes indications
Expected 2026-2027:
Potential FDA approval and commercial launch
Frequently Asked Questions
Is Foundayo the same as orforglipron?
Yes. Foundayo is the brand name chosen by Eli Lilly for orforglipron (LY3502970). They are the same compound — a non-peptide oral GLP-1 receptor agonist.
Is Foundayo as effective as Ozempic?
Phase 3 ATTAIN-1 data shows meaningful weight loss. Direct cross-drug comparisons depend on study population and dose, but oral convenience is a major advantage for adherence.
Can I really take it with food?
Yes. Unlike Rybelsus, Foundayo's small molecule structure allows absorption regardless of food intake. Take it with any meal or without food — no restrictions.
Why daily instead of weekly?
Small molecules are cleared faster than peptides. Daily dosing with zero restrictions may be preferable to weekly injections or weekly pills with strict fasting rules.
Leitfaden-FAQ
Topisch zur Hautverjüngung und Haarpflege. Injizierbar in der Forschung für systemische Regeneration und Anti-Aging.
Bei topischer Anwendung zeigen Studien oft nach 8–12 Wochen messbare Verbesserungen der Hautdichte.
Präklinische Daten deuten darauf hin, dass es die Haarfollikel-Proliferation stimuliert und die Wachstumsphase verlängert.
Quellen
Verfolgen Sie Ihr Foundayo-Protokoll in Shotlee
Kostenlose Protokollierung von Dosen, Nebenwirkungen und Gesundheitswerten für Ihr gesamtes Foundayo (Orforglipron)-Protokoll.
🚀 Shotlee kostenlos nutzen